IGF::OT::IGF STATIN THERAPY TO REDUCE DISEASE PROGRESSION FROM LIVER CIRRHOSIS TO CANCER

IGF::OT::IGF 他汀类药物治疗可减少从肝硬化到癌症的疾病进展

• 批准号: 9369104
• 负责人: SEEMA KHAN
• 金额: $ 62.64万
• 依托单位: NORTHWESTERN UNIVERSITY AT CHICAGO
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-09-15 至 2018-09-14
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9369104
• 关键词: AFP gene; Bile Acids; Clinic; Disease Progression; Evaluation; Hepatology; Interleukin-6; Intervention; Liver; Liver Cirrhosis; Liver diseases; Malignant Neoplasms; Medical center; Modeling; Participant; Patients; Phase; Placebos; Primary carcinoma of the liver cells; Recruitment Activity; Serum; Simvastatin; Staging; Universities; double-blind placebo controlled trial; liver transplantation

The proposed study is a Phase IIb, double-blinded, placebo-controlled trial of a statin to evaluate the impact of statin treatment on disease progression in 80 patients with liver cirrhosis who have a current Model for End-Stage Liver Disease (MELD) ≤ 20 and no evidence of Hepatocellular carcinoma (HCC). Participants shall be recruited from hepatology clinics at Cedar Sinai Medical Center (CSMC) and Northwestern University (NWU) and shall include patients who are currently waitlisted, or under evaluation, for a liver transplant.

这项拟议的研究是一项他汀类药物的IIb期双盲安慰剂对照试验，以评估他汀类药物对80名肝硬变患者的疾病进展的影响，这些患者目前的终末期肝病模型(MELD)为≤20，没有肝细胞癌的证据。参与者应从锡达西奈医学中心(CSMC)和西北大学(NWU)的肝病诊所招募，并应包括目前正在等待或正在评估中的肝移植患者。